Core Viewpoint - Aethlon Medical, Inc. is set to release its financial results for the fiscal third quarter ending December 31, 2025, on February 12, 2026, at 4:15 p.m. ET [1] Group 1: Financial Results Announcement - The financial results will be discussed in a conference call on February 12, 2026, at 4:30 p.m. ET, which will include a question and answer session [2] - Interested parties can register for the conference call online, and registered participants will receive a dial-in number [2] Group 2: Conference Call Access - For those without internet access, a toll-free number is available for participation in the conference call [3] - A replay of the call will be accessible approximately one hour after the call ends and will be available until March 12, 2026 [4] Group 3: Company Overview - Aethlon Medical focuses on developing the Hemopurifier, an immunotherapeutic device aimed at treating cancer and life-threatening viral infections [5] - The Hemopurifier has shown promise in human studies for removing life-threatening viruses and harmful exosomes, which may have applications in cancer treatment [5] - The device has received FDA Breakthrough Device designation for treating advanced or metastatic cancer and life-threatening viruses not addressed by approved therapies [5]

Q4 2025 Highlights February 4, 2026 1 Q4 2025 Financial & Operational Highlights | February 4, 2026 Forward-Looking Statements and Use of Document Forward-looking statements: FCF is a non-GAAP measure calculated as operating cash flows less net purchases of property, plant, and equipment and internal use software. FCF Conversion is a non-GAAP measure calculated as FCF divided by adjusted net income available to common stockholders. Emerging Markets: Our Emerging Markets countries include all countries excep ...

Core Insights - Catheter Precision, Inc. has reported a surge in hospital evaluations and approvals for its LockeT suture retention device, indicating strong progress in product adoption both domestically and internationally as of Q1 2026 [1][2] Product Adoption - The company achieved its highest recorded revenue for January and has entered several international markets, securing evaluations at additional high-volume centers in the U.S. These evaluations are essential for long-term purchasing agreements [2] - Initial feedback from hospital partners suggests that LockeT effectively addresses the need for efficient and cost-effective wound closure, with expectations for evaluations to transition into permanent adoption [3] Product Details - LockeT is a Class 1 suture retention device registered with the FDA and has received CE Mark approval, designed to assist in wound closure after percutaneous venous punctures [4] Company Overview - Catheter Precision is a U.S.-based medical device company focused on innovative solutions for cardiac arrhythmias, emphasizing collaboration with physicians to advance electrophysiology procedures [5] Operational Efficiency - LockeT's design allows for rapid staff onboarding, with training completed in several days at major institutions, enhancing operational efficiency [9] - The device facilitates same-day discharge and reduces post-procedural bed rest, presenting a strong economic case for hospitals [9] International Expansion - The company is expanding into the European closure market, leveraging its CE Mark approval and the economic advantages of LockeT [9]

Company Closures and Layoffs - CNH Industrial America is closing its Burlington, Iowa plant, resulting in 209 layoffs by May 2026 due to lower backhoe demand [1] - Continental Tire of America will close its Barnesville, Georgia manufacturing plant, laying off 235 employees by the end of 2026, citing long-standing cost-competitiveness issues [2] - Alton Steel Inc. will cease operations in Alton, Illinois, impacting approximately 253 employees, due to structural challenges in the domestic steel industry [3] - Macy's Inc. will close its Owasso, Oklahoma fulfillment center by the end of March, resulting in 993 layoffs as part of a supply chain modernization effort [4] - King Delivery LLC is closing operations in Brooklyn, New York, leading to 153 layoffs [6] - Fresenius USA Manufacturing will lay off 165 employees across three distribution centers due to the divestiture of parts of its logistics operation [7][8] - Kuehne+Nagel Inc. plans to close its Locust Grove, Georgia logistics operation, resulting in 153 layoffs [9] - Legacy Supply Chain is laying off 129 employees across five California locations [10] - American Eagle Outfitters is shutting down its La Palma fulfillment center, eliminating 108 jobs [11][12] - FTI Buyer LLC will close its Cincinnati facility, laying off 104 employees [13] - First Brands Group is closing its Arlington facility, affecting 88 employees [14] - Goodyear Tire & Rubber Co. plans to close its Tall Timbers Mold facility in Findlay, Ohio, resulting in 85 layoffs [15] - Lighteum Medical is laying off 83 employees at its San Diego facility [16] - Plug Power Inc. filed a WARN notice for a mass layoff at its Houston facility, affecting 74 employees [17] - Great Lakes Coca-Cola Distribution will lay off 62 employees in Lansing, Michigan [18] - Waddington North America is closing a facility in Bremen, Georgia, eliminating 49 jobs [19] - Turf Care Supply Corp. will close its blending department, eliminating 46 jobs [20] - Automated Harvesting LLC is closing its Yuma operations, laying off 46 workers [21] - H4 Logistics LLC is closing its Kenosha facility, resulting in 41 layoffs [22] - Tekni-Plex plans to close its Milwaukee facility, impacting 39 employees [23] - GXO Logistics will close its Romeoville facility, laying off 32 workers [25] Industry Trends - Weak consumer demand, excess capacity, contract losses, and network consolidation are leading shippers and logistics providers to shrink operations [5] - Manufacturers tied to industrial freight are cutting output amid slower order volumes and tighter capital conditions, reflecting a freight market struggling to regain momentum [5]

Core Viewpoint - GE HealthCare has projected annual profit exceeding Wall Street estimates, driven by strong demand for its diagnostic and imaging devices [1] Group 1: Financial Forecast - The company anticipates annual profit to surpass market expectations, indicating positive financial performance [1] Group 2: Market Demand - There is a robust demand for GE HealthCare's diagnostic and imaging devices, which is a key factor in the company's optimistic profit forecast [1]

Core Insights - Boston Scientific has reported strong growth in its electrophysiology sales, particularly in the pulsed field ablation (PFA) market, positioning itself as a market leader [1][2]. Financial Performance - Q4 sales reached $5.29 billion, marking a nearly 16% increase year over year [1]. - Electrophysiology sales for Q4 totaled $890 million, reflecting a 37% year-over-year growth [1][3]. - Projected sales for 2025 are $20.07 billion, indicating a nearly 20% increase year over year [1]. - Electrophysiology sales for 2025 are expected to reach $3.33 billion, showing a significant 74.6% growth year over year [1]. Market Dynamics - Despite strong overall performance, U.S. sales growth for the electrophysiology unit stalled in Q4 compared to Q3, raising concerns among analysts [2][3]. - CEO Mike Mahoney expressed confidence in the PFA market's potential, anticipating a growth rate of about 15% in 2026, with expectations for the company to exceed this rate [2]. - The slowdown in growth may be attributed to increased market penetration and a shift in treatment approaches for atrial fibrillation, with approximately 70% of ablation procedures in the U.S. utilizing PFA in 2025 [6]. Investor Sentiment - Analysts have expressed concerns regarding the trajectory of key growth drivers, particularly after the flat U.S. sales performance in Q4, leading to a nearly 16% drop in the company's stock price [4]. - The company experienced a notable slowdown in electrophysiology growth, with previous quarters showing much higher growth rates, such as 143% in Q1 2025 and 96% in Q2 2025 [5].

New York, New York--(Newsfile Corp. - February 4, 2026) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Integer Holdings Corporation (NYSE: ITGR) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Integer, you are encouraged to obtain additional information by visiting: https://www.bfala ...

BOULDER, CO / ACCESS Newswire / February 4, 2026 / Encision Inc. (OTC PINK:ECIA), a medical device company owning patented Active Electrode Monitoring (AEM®) Technology that prevents dangerous radiant energy burns in minimally invasive surgery, today reported its financial results for its 2026 fiscal third quarter. Encision's CEO Robert Fries commented, "The Company's revenue has continued to decline principally because of procedures that were performed by surgical robots that have replaced our surgical pro ...

123 MARLBOROUGH, Mass., Feb. 4, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $5.286 billion during the fourth quarter of 2025, growing 15.9 percent on a reported basis, 14.3 percent on an operational basis and 12.7 percent on an organic basis, all compared to the prior year period. The company reported GAAP net income attributable to Boston Scientific common stockholders of $672 million or $0.45 per share (EPS), compared to $566 million or $0.38 per share a year ago, ...

Core Insights - The article discusses the challenges faced by millions who stop using GLP-1 weight loss drugs due to side effects, high costs, or supply issues, and highlights emerging alternatives for weight management [11]. Group 1: Demand for Alternatives Due to GLP-1 Discontinuation - GLP-1 drugs like Semaglutide (Ozempic, Wegovy) and Tirzepatide (Zepbound) have a high discontinuation rate of 37% to 81% within the first year, prompting patients to seek sustainable alternatives [12]. - Factors such as unstable drug supply, annual costs averaging tens of thousands of dollars, and side effects like nausea are driving patients towards traditional weight loss methods [12]. - The popularity of GLP-1 drugs has led to renewed interest in traditional weight loss methods, creating a new treatment paradigm of "drug initiation followed by diverse follow-up" [12]. Group 2: Innovations in Surgical and Endoscopic Techniques - Traditional weight loss surgeries, such as gastric bypass and sleeve gastrectomy, have been shown to achieve long-term weight loss of 30% to 50%, but global surgical penetration remains below 1% due to patient concerns about surgical trauma [13]. - The 2022 international guidelines lowered the BMI threshold for surgical eligibility, and institutions like the Mayo Clinic are exploring "drug-surgery sequential treatment" to enhance outcomes [13]. - Endoscopic techniques are gaining attention, including Endoscopic Sleeve Gastroplasty (ESG) and Gastric Mucosal Ablation (GMA), which are less invasive and have shown promising results [14][15]. Group 3: Challenges in Promotion and Payment Systems - Despite the potential of endoscopic techniques, their global adoption faces challenges such as limited insurance coverage and the need for standardized operational techniques [16]. - The average out-of-pocket cost for ESG is around $6,000, and GMA is not yet covered by insurance [16]. - There is a push in countries like Brazil to establish multidisciplinary weight management centers that integrate drug, endoscopic, and surgical resources to improve overall treatment quality [16].